BackATAI Life Sciences N.V. Overview
ATAI Life Sciences N.V.

ATAI Life Sciences N.V. Target Price

Analysts' average 12-month price target for ATAI Life Sciences N.V. is $9.2.

Get informed when a big investor buys or sells

+ Follow

Share Price

$7.35

Average Target Price

$9.2425.7% upside

6 analysts in the last 4 months

High: $17 | Low: $7.45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-12Deutsche BankDavid Hoang$88.8% upsideOpen
2026-07-20H.C. WainwrightPatrick Trucchio$7.52% upsideOpen
2026-07-20Berenberg Bank$7.451.4% upsideOpen
2026-07-16Jefferies$7.52% upsideOpen
2026-07-16Canaccord Genuity$88.8% upsideOpen
2026-07-07Canaccord Genuity$17131.3% upsideOpen
2026-04-20Canaccord GenuitySumant Kulkarni$15104.1% upsideOpen
2026-03-27Deutsche Bank$1263.3% upsideOpen
2026-03-06JefferiesAndrew Tsai$1036.1% upsideOpen
2026-01-20Guggenheim$1149.7% upsideOpen
2025-10-22Canaccord Genuity$1490.5% upsideOpen
2025-10-13Needham$1263.3% upsideOpen
2025-05-20JefferiesAndrew Tsai$532% downsideOpen
2024-04-03Maxim GroupJason McCarthy$618.4% downsideOpen

ATAI Life Sciences N.V. (ATAI) FAQ

ATAI Life Sciences N.V.'s target price stands at $9.2. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $9.2 for ATAI implies 25.7% upside versus today's price ($7.35). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how ATAI Life Sciences N.V.'s target price evolved across reporting periods, while the comparison chart places ATAI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. ATAI Life Sciences N.V.'s reading of $9.2 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.